Loading
A phase 3 trial testing GQ1005 in HER2-positive breast cancer, now recruiting.
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT07673029, led by GeneQuantum Healthcare (Suzhou), and recruiting on the registry. Official title: A Phase III, Multicenter, Open-label, Randomised Controlled Study Comparing GQ1005 and Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane. Planned enrolment is 228 participants (estimated). The study started in 2025-01-10 and primary completion is expected in 2027-01-09. No results have been posted on ClinicalTrials.gov.